1) intimal proliferation
内膜增殖
1.
The rat model of intimal proliferation were copied by injuring aortic intima with self-made balloon.
各组采用球囊内膜剥脱法复制大鼠主动脉内膜增殖动物模型,每组自造模前1 d开始,分别静脉注射化瘀通脉注射液、丹参注射液和生理盐水,于造模后第5,10,15,25 d每组各随机选取8只大鼠取血,检测各组血浆ET-1、NOI、CAM-1含量。
2.
Objective: To study the effect of Huayutongmai Injection on intimal proliferation of rat aorta after balloon injury.
目的:观察化瘀通脉注射液对大鼠主动脉球囊损伤后内膜增殖的影响。
3.
Intimal proliferation is a leading cause of restenosis after percutaneous coronary intervention.
内膜增殖是经皮冠状动脉介入治疗后再狭窄的主要原因,包括中膜血管平滑肌细胞表型转化、增殖、迁移至内膜并合成大量的细胞外基质。
2) neointimal proliferation
内膜增殖
1.
Effectiveness of recombinant hirudin locally delivered via a porous balloon on lessening neointimal proliferation and luminal stenosis after balloon angioplasty in rabbits;
重组水蛭素局部治疗球囊扩张术后内膜增殖和管腔狭窄的实验研究
2.
Effectiveness of recombinant hirudin locally delivered via a porous balloon on reducing neointimal proliferation and luminal stenosis after balloon angioplasty in a rabbit model;
重组水蛭素局部治疗兔髂总动脉球囊扩张术后内膜增殖和管腔狭窄
3.
Effect of recombinant hirudin in reducing neointimal proliferation after balloon angioplasty of normal iliac arteries in rabbits;
重组水蛭素对兔髂总动脉球囊损伤后内膜增殖影响的实验研究
3) Intimal hyperplasia
内膜增殖
1.
RT-PCR, immunohistochemical staining and histochemical staining were used to detect the c-myc mRNA, Ki67 antigen and the degree of intimal hyperplasia.
目的评估酪氨酸蛋白激酶抑制剂2,5-MC抑制支架植入术后内膜增殖的效果。
2.
Objective and backgroundInflammation and platelet may be very important in the progress of intimal hyperplasia, and the letter is the principle mechanism of restenosis after PTC A.
流行病学、基础及临床实验均表明肺炎衣原体(CP)与动脉粥样硬化(AS)及血管内膜增殖有关。
4) neointima formation
内膜增殖
1.
Influence of bone marrow-derived EPCs to neointima formation;
大鼠骨髓源性内皮祖细胞对损伤后血管内膜增殖的影响
5) Endometrial hyperplasia
子宫内膜增殖症
1.
A clinical pathogical analysis of 186 cases of endometrial hyperplasia;
子宫内膜增殖症186例临床病理分析
2.
Methods The expression of Fhit protein and p53 protein in 37 normal endometrial tissues,55 endometrial hyperplasia tissues and 38 endometrial adenocarcinomas were examined by S-P immunohistochemical method.
目的 探讨正常子宫内膜、子宫内膜增殖症及内膜癌组织中Fhit、p53蛋白表达,以及与子宫内膜癌发生、发展的关 系。
3.
Methods The expression of PTEN and Ki 67 proteins was detected by immunohistochemical staining S P method in 12 cases of normal proliferative endometrium and 40 cases of endometrial hyperplasia and 42 cases of endometrial adenocarcinoma.
方法 应用免疫组化S P法对 12例正常增生期子宫内膜组织、4 0例子宫内膜增殖症组织、4 2例内膜腺癌组织中PTEN、Ki 6 7蛋白的表达进行研究。
6) endometrial hyperplasia
子宫内膜增殖
1.
Aromatasecy p450 expression and clinical application in the tissues of endometrial hyperplasia and atypical hyperplasia;
芳香化酶P450在子宫内膜增殖及非典型增殖组织中的表达
补充资料：子宫内膜癌腔内放射治疗
子宫内膜癌腔内放射治疗
子宫内膜癌腔内放疗有：①传统方法，使用治疗子宫颈癌的治疗容器，如宫腔管及阴道容器，(容器有：斯德哥尔摩盒式、巴黎弓形、曼彻斯特卵圆形、北京型等)。其缺点是子宫角部受量不足；②Heyman倡导宫腔填充法，将含有镭或其他同位素的金属小囊填满于子宫腔内，使宫腔各壁均能得到高剂量照射，可使单纯放疗效果由30%～40%增至60%以上；③腔内后装放射治疗。剂量：现在采用高剂量率及中剂量率，摒弃低剂量率。高剂量率：Ⅰ期：A点(位于子宫旁三角区内，代表宫旁正常组织受量)总剂量36～40Gy，F点(位于宫腔放射源的顶端旁开子宫中轴2cm，代表肿瘤部受量)总剂量40～45Gy。腔内治疗分5～6次进行，每周1次，每次剂量大致相同。Ⅱ期～Ⅲ期：A点及F点总剂量均为45～50Gy，腔内治疗分6～7次，每周1次，每次剂量大致相同。中剂量率：Ⅰ期：A点总剂量率45～50Gy，F点总剂量50～55Gy，腔内治疗6～8次，每周1次，每次剂量基本相似，Ⅱ～Ⅲ期：A点及F点剂量均为55～60Gy，腔内治疗7～8次，每周1次，每次剂量大致相同。腔内照射多用137Cs、60Co等。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条